The PIONEER Study, a Phase 2 Clinical Study of T3D-959 in Mild to Moderate Alzheimer’s Subjects has Completed. Results Presented at CTAD 2023 (Click to learn more)Welcome to T3D Therapeutics
T3D Therapeutics, Inc. was founded in 2013 to challenge the prevailing thinking over the last two decades in the development of solutions to effectively treat Alzheimer’s disease. Our mission is to develop a ground-breaking, disease-modifying, new drug for the treatment of Alzheimer’s disease (AD). Additionally, T3D Therapeutics is targeting treatments for other other neurodegenerative diseases with an emphasis on Huntington’s Disease (HD).
Fundamental to our approach to AD is the recognition that Alzheimer’s disease (refs.1-5) is a neuro-metabolic disease and, as such, we must first address poor energy metabolism and dysfunctional lipid metabolism in the brain – brain ‘starvation’ – which leads to neurodegeneration and brain ‘strangulation’, as evidenced by plaques, tangles and inflammation of the brain (ref. 6).
The brain is the most metabolically active organ in the body and it relies on glucose, or sugar, for fuel (ref. 7). If the brain loses its ability to efficiently process sugar into energy and maintain lipid homeostasis, the brain becomes starved. This ‘starvation’ causes a wasting process that then leads to cognitive and motor function deficits – this is Alzheimer’s disease.
Our lead product candidate, T3D-959, is positioned to become a transformational therapy by targeting both the brain ‘starvation’ and neurodegeneration of Alzheimer’s disease and by treating multiple manifestations of the disease.
%
The brain accounts for only 2% of total body weight.
%
Oxygen is vital to metabolism. The adult brain uses 20% of the body's total oxygen consumption.
%